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Abstract
Background: 4-Aminobiphenyl (ABP) is an established human bladder carcinogen, with tobacco smoke
being a major source of human exposure. Other arylamine compounds, including 2,6-dimethylaniline
(2,6-DMA), have been implicated as possible human bladder carcinogens. Hemoglobin adducts of 4-ABP
and 2,6-DMA are validated biomarkers of exposure to those compounds in humans.
Methods: The Shanghai Bladder Cancer Study enrolled 581 incident bladder cancer cases and 604
population controls. Each participant was solicited for his/her history of tobacco use and other lifestyle
factors and donation of blood and urine specimens. Red blood cell lysates were used to quantify both
hemoglobin adducts of 4-ABP and 2,6-DMA. Urine samples were used to quantify total cotinine. ORs and 95%
confidence intervals (CI) for bladder cancer were estimated using unconditional logistic regression methods.
Results: Among lifelong nonsmokers, ORs (95% CIs) of bladder cancer for low (below median of positive
values) and high versus undetectable levels of 2,6-DMA hemoglobin adducts were 3.87 (1.39–10.75) and 6.90
(3.17–15.02), respectively (Ptrend < 0.001). Similarly, among lifelong nonsmokers, ORs (95% CIs) of bladder
cancer for third and fourth versus first/secondquartiles of 4-ABPhemoglobin adductswas 1.30 (0.76–2.22) and
2.29 (1.23–4.24), respectively (Ptrend ¼ 0.009). The two associations were independent of each other.
Conclusion:Hemoglobin adducts of 4-ABP and 2,6-DMAwere significantly and independently associated
with increased bladder cancer risk among lifelong nonsmokers in Shanghai, China.
Impact:The findings of the present study in China with previous data in Los Angeles, California strongly
implicate arylamines as potential causal agents of human bladder cancer. Cancer Epidemiol Biomarkers Prev;
22(5); 937–45. 2013 AACR.
Introduction
Early observational studies show significantly
increased incidence of bladder cancer among workers
occupationally exposed to arylamines in the workplace,
and subsequent studies led to the discovery and confir-
mation of certain arylamines, including 4-aminobiphenyl
(4-ABP), 2-naphthylamine, and benzidine, to be carcino-
genic to humans. They are classified as group I carcino-
gens by the International Agency for Research on Cancer
(IARC; ref. 1).
Following governmental regulation of industrial use of
arylamines in 1970s, tobacco smoke emerged as the major
source of 4-ABP exposure in humans (2). Tobacco use is
recognized as an important risk factor for bladder cancer.
Smokers exhibit 2- to 3-fold of excess risk for bladder
cancer compared with nonsmokers (3). In our case–con-
trol study in Los Angeles, California, smokers exhibit
more than 3 times higher levels of 4-ABP hemoglobin
adducts, a validated biomarker of 4-ABP exposure, than
lifelong nonsmokers (4).
Although tobacco use is a known major risk factor for
bladder cancer, it only accounts for roughly 50%ofdisease
burden in the United States (5). Relatively little is known
about the causes of nonactive smoking related bladder
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cancer. We have reported environmental tobacco smoke
(ETS) exposure as a risk factor for nonsmoking-related
bladder cancer (6, 7). The data were based on 2 separate
but parallel case–control studies conducted in Los
Angeles, California (high-risk region; The Los Angeles
Bladder Cancer Study) and Shanghai, China (low-risk
region; The Shanghai Bladder Cancer Study). The Los
Angeles Study further implicates other diffuse sources
of 4-ABP (besides active and passive smoking) as possible
causal factors for nonsmoking-related bladder cancer.
More significantly, The Los Angeles Study examined
hemoglobin adducts of nine alkylanilines, a subclass of
arylamines that was previously unstudied in relation to
bladder cancer risk, and found 3 of them, including 2,6-
dimethylaniline (2,6-DMA), to be independently and sig-
nificantly associated with bladder cancer risk among
nonsmoking subjects at blooddraw. Experimental studies
have shown that administration of 2,6-DMA in the diet
can induce adenomas and carcinomas as well as several
sarcomas in the nasal cavity of rats. 2,6-DMA also pro-
duces subcutaneous fibromas and fibrosarcomas and
increases the incidence of neoplastic nodules in the livers
of rats (8, 9). 2,6-DMA is classified by IARC as a group 2B
carcinogen (possibly carcinogenic to humans; refs. 9, 10).
Arylamines require metabolic activation, usually in the
liver, to be transformed into fully carcinogenic agents (11).
They are oxidized to N-hydroxylamines in vivo and react
with hemoglobin to form adducts that may persist for as
long as the hemoglobin adducts remains in circulation
(4, 12). In the acidic environment of the bladder lumen, a
derivative of the glucuronide conjugates of N-hydroxy-
lamines can covalently bind to urothelial DNA and cause
malignant transformation of urothelial cells, which may
ultimately lead to bladder cancer (13). Hemoglobin
adducts of arylamines are validated biomarkers of aryla-
mine exposure in humans (14). These adducts represent
both the uptake of arylamines and their genetically con-
trolled metabolism in individual subjects.
Here, we report the findings of the Shanghai Bladder
Cancer Study on hemoglobin adducts of 4-ABP and 2,6-
DMA in relation to bladder cancer risk. The results are
consistent with our prior novel findings in Los Angeles
(4, 12) and strongly implicate arylamines as major causal
agents of bladder cancer, not only among tobacco users
but in lifelong nonsmokers as well.
Materials and Methods
Subjects
Thepresent study includedparticipants of the Shanghai
Bladder Cancer Study. The study design has been
described in detail elsewhere (7). Briefly, patients with
bladder cancer were identified through the Shanghai
Cancer Registry, a population-based cancer registry cov-
ering the approximately 8 million residents of urban area
in Shanghai, China, in the 1990s.Of thepatients diagnosed
with bladder cancer from July 1, 1995, to June 30, 1998, 708
were 25 to 74 year old who met our eligibility criteria for
the study. Among the 708 patients, 56 died before we
could contact them, 29 refused to be interviewed, and 42
were unable to be located. We interviewed the remaining
581 (82%) eligible patients between July 1996 and June
1999. The diagnosis of bladder cancer for 531 (91%)
patients was made based on histopathologic evidence,
whereas the remaining 50 (9%) patients diagnoses were
based on positive computerized axial tomography scan
and/or ultrasonograph with consistent clinical history.
Control subjects were randomly selected from the urban
population of Shanghai through the Residents Registry of
the Shanghai Municipal Government. They were chosen
to match the frequency distribution by sex and 5-year age
groups of patients with bladder cancer. Among the 750
potential control subjects chosen, 604 (81%) eligible sub-
jects were interviewed during the same time period as the
cases. All subjects provided informed consent following
procedures approved by the appropriate institutional
review boards.
Data collection
A trained interviewer conducted an in-person inter-
viewwith each study subject using a structured question-
naire. The questionnaire asked for information on sub-
jects’ demographic characteristics, history of tobacco use,
history of passive smoking (for nonsmokers only), con-
sumption of beverages, use of hormones (for women
only), medical history, usual adult diet, and occupational
history. Cigarette smoking was defined as smoking 1
cigarette per day for at least 6 months. Lifelong nonsmo-
kers were defined as subjects who were not smoking on a
regular basis in the past 6months before the reference date
(2 years before cancer diagnosis for cases and 2 years
before interview for controls) andwho did not smoke any
cigarettes in the past 6 months prior to the date of blood
and urine sample collection. All subjects whose urinary
level of cotininewas75 ng/mLwere defined as smokers
at the time of urine sample collection.
All subjects were asked to donate blood and an over-
night urine sample (endingwith the firstmorning void) at
the end of the in-person interview. A total of 513 (88% of
interviewed) cases and 534 (88% of interviewed) controls
provided a blood sample. Blood sampleswere collected in
heparinized (10 mL) and nonheparinized (4 mL) tubes.
Heparinized samples were fractioned into plasma, buffy
coat, and erythrocytes on the day of the sample collection
andwere stored at80C.When picking up the overnight
urine sample, the interviewer asked the subject about
use of tobacco products during the past 60 days. Five
hundred and thirty-five (92%) of case patients and 543
(90%) of interviewed control subjects donated an over-
night urine sample. The urine samples were processed on
the day of collection and acidified (400mg of ascorbic acid
per 20mL of urine) before theywere stored at80Cuntil
analysis.
Laboratory measurements
Arylamine hemoglobin adducts. Erythrocyte frac-
tions, identifiable only by their code numbers, were set
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on dry ice and sent to the University of Pittsburgh, where
they were stored at 30C until assays for arylamine-Hb
adducts were conducted. Hemoglobin adducts of 4-ABP
adducts and 2,6-DMA were quantified using the internal
standards [methyl-2H6]-2,6-dimethylaniline and 4-fluoro-
40-aminobiphenyl as described previously (12, 15). Eryth-
rocyte fractions were thawed and 1 mL of each were
centrifuged at 1,000 g for 10minutes to pellet cell debris.
The mixture was then dialyzed for 36 hours against 50
volumes of water using a dialysis bath at 4C and chang-
ing dialysis bath water twice to remove noncovalently
bound low–molecular weight compounds. The hemoglo-
bin concentration in each sample was determined by
Drabkin’smethod. Each dialyzed samplewas then spiked
with the internal standards, the sulfinamide bonds
between the electrophilic forms of the arylamines and the
sulfur of b93-cysteine residue of hemoglobin were hydro-
lyzed with aqueous NaOH. The freed arylamines were
then extracted into hexane and derivatized with penta-
fluoropropionic anhydride. The resulting amides were
concentrated under a stream of dry nitrogen, redissolved
in iso-octane, and analyzed by GC-NICI-SIM-MS using a
Carbowax capillary column.
Urinary total cotinine. Cotinine is a major proximate
metabolite of nicotine but has a longer half-life than
nicotine. Therefore, cotinine is a better biomarker for daily
use of cigarettes than nicotine itself and other nicotine
metabolites. In the present study, urinary cotinine was
measured by the standard gas chromatographic-mass
spectrometric method (GC-MS; ref. 16).
Statistical analysis
In the present study, we included 494 (85% of inter-
viewed) case patients and 499 (83% of interviewed)
control subjects with available measurement of aryla-
mine hemoglobin adducts. Bladder cancer cases includ-
ed in this study were comparable with those excluded
from the study in terms of age at diagnosis, body mass
index, level of education, and smoking status at refer-
ence (all P > 0.05). Given the skewed distribution of 4-
ABP hemoglobin adducts, formal statistical test was
conducted on logarithmically transformed values, and
geometric (as opposed to arithmetic) means were pre-
sented. The analysis of covariance (ANCOVA) method
was applied to identify determinants of 4-ABP in all
control subjects. Number of cigarettes smoked per day
(0, 1–<10, 10–<20, and 20þ) at blood draw and urinary
levels of cotinine (0, 1–<100, 100–<500, and 500þ ng/
mL) were found to be significantly associated with
levels of 4-ABP hemoglobin adducts. Thus, in all sta-
tistical analysis that included smokers at the time of
blood/urine collection, the latter 2 factors were part of
the covariates set in regression models, in addition to
gender, age at blood draw, and level of education.
The c2 and nonparametric statistics methodswere used
to examine the difference in distributions of 2,6-DMA
hemoglobin adducts across different exposures (i.e.,
smoking or urinary total cotinine) among controls given
the skewed distribution of the data and small percentage
(6%) of controlswith detectable level of 2,6-DMAadducts.
The samemethodswere used to examine the difference in
distributions of 2,6-DMA adducts between cases and
controls.
Unconditional logistic regression models were used
to examine the associations between adducts and risk of
bladder cancer. A high proportion of study subjects
(72% controls and 91% cases) in our study had unde-
tectable level of 2,6-DMA adducts. We classified sub-
jects who had detectable level of 2,6-DMA into low
(below median of positive values in controls) and high
levels of exposure. The median value in controls was
determined to be 115.9 pg/g hemoglobin. Similarly, we
grouped subjects by quartiles based on the distribution
of 4-ABP adducts in controls. The strength of the asso-
ciation between levels of adducts and bladder cancer
risk was measured by ORs and their corresponding 95%
confidence intervals (CI) and P values. We assessed the
associations in total subjects and in subgroups defined
by cigarette smoking status at blood draw and by
smoking history over lifetime.
Statistical analyses were conducted using SAS version
9.2 (SAS Institute) statistical software package. All P
values are 2-sided. P < 0.05 was considered statistically
significant.
Results
The mean age (SD) of case patients at diagnosis of
bladder cancer was 63.6 (9.9), years whereas the mean
age of control subjects at interview was 64.0 (10.0)
years (P ¼ 0.74). Eighty percent of patients with bladder
cancer and 77% of control subjects were men (P ¼ 0.29).
Case patients had similar distributions as control sub-
jects by levels of education and body mass index (Table
1). More case patients were current smokers and exhib-
ited greater number of pack-years of smoking than
controls at the reference date (i.e., 2 years before cancer
diagnosis for case patients and 2 years before interview
for control subjects; Table 1). However, fewer patients
with bladder cancer smoked cigarettes during the
past 60 days before blood draw. Case patients and
control subjects had comparable levels of total cotinine
in urine collected around the same time as the blood
draw (Table 1).
2,6-DMA adducts were detected in 136 (26%) of 484
bladder cancer cases and 31 (6%) of 499 control subjects (P
< 0.001). Among control subjects, therewas no statistically
significant difference in 2,6-DMA adducts levels between
current smokers at blood draw and lifelong nonsmokers
or across different levels of smoking (i.e., number of
cigarettes per day at blood draw or urinary total cotinine).
Among subjects with positive 2,6-DMA adducts, the dif-
ference in 2,6-DMA adducts between cases and controls
[median: 233.9 in cases vs. 115.9 pg/g hemoglobin in
controls; geometric mean: 232.0 (95% CI, 176.3–307.6) in
cases vs. 162.2 (95%CI, 89.6–293.6) pg/g hemoglobin]was
not statistically significant (P > 0.13) (data not shown).
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Compared with subjects who had undetectable adducts,
individuals exhibiting low (below median of positive
values) and high (above median of positive values) levels
had an OR of 4.08 (95% CI, 2.16–7.70) and 7.38 (95% CI,
4.16–13.07), respectively, for bladder cancer after adjust-
ment for potential confounders (Ptrend < 0.001; Table 2).
The positive association between 2,6-DMA hemoglobin
adducts and bladder cancer riskwas present separately in
smokers and nonsmokers at blood draw, as well as in
lifelong nonsmokers.
Among controls, geometric means of 4-ABP adducts
increased with increasing number of cigarettes smoked
per day at blood draw as well as increasing levels of
urinary cotinine (both Ptrend < 0.001; Table 3). Levels of
4-ABP adducts were comparable betweenmen andwom-
en after differences in number of cigarettes per day, and
urinary total cotinine between the 2 sexes were taken into
account (data not shown). There was no correlation
between 4-ABP and 2,6-DMA adducts among control
subjects (correlation coefficient ¼ 0.03, P ¼ 0.764).
Table 1. Distributions of selected characteristics among patients with bladder cancer (cases) and control
subjects, The Shanghai Bladder Cancer Case-Control Study, 1995–1998
No. cases (%) No. of controls (%) P
Total subjects 484 (100) 499 (100)
Age at blood draw, y 0.466
<50 64 (13.2) 50 (10.0)
50–<60 60 (12.4) 65 (13.0)
60–<70 212 (43.8) 222 (44.5)
70 148 (30.6) 162 (32.5)
Gender 0.290
Male 385 (79.6) 383 (76.8)
Female 99 (20.5) 116 (23.3)
Education 0.518
No formal schooling 39 (8.1) 39 (7.8)
Primary school 121 (25.0) 123 (24.7)
Middle school 265 (54.8) 290 (58.1)
College and above 59 (12.2) 47 (9.4)
Body mass index, kg/m2 0.191
<18.5 (underweight) 42 (8.7) 46 (9.2)
18.5–24.9 (normal) 347 (71.7) 377 (75.6)
25 (overweight and obese) 95 (19.6) 76 (15.2)
Smoking status at reference date <0.001
Never smokers 166 (34.3) 223 (44.7)
Former smokers 76 (15.7) 84 (16.8)
Current smokers 242 (50.0) 192 (38.5)
No. of pack-years of smoking
0 (never smokers) 166 (34.3) 223 (44.7) 0.002
<20 123 (25.4) 115 (23.1)
20–<40 94 (19.4) 94 (18.8)
40 101 (20.9) 67 (13.4)
No. of cigarettes smoked/d in the past 60 d before blood draw <0.001
0 (nonsmokers) 357 (73.8) 309 (61.9)
<10 cigarettes/d 58 (12.0) 55 (11.0)
10–<20 cigarettes/d 37 (7.6) 57 (11.4)
20þ cigarettes/d 32 (6.6) 78 (15.7)
Lifetime never smokersa 158 (32.6) 210 (42.1) <0.001
Urinary levels of total cotinine, ng/mL 0.109
0 (undetectable) 196 (40.5) 174 (34.9)
1–<100 139 (28.7) 147 (29.5)
100–<500 52 (10.7) 68 (13.6)
500 58 (12.0) 79 (15.8)
Unknown 39 (8.1) 31 (6.2)
aSelf-reported nonsmoking at both baseline and blood draw, and urinary cotinine <75 ng/mL.
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Table 4 shows the associations between 4-ABP hemo-
globin adducts and risk of bladder cancer. No statistically
significant associations were observed in total subjects.
However, among lifelongnonsmokers, adose-dependent,
statistically significant association between 4-ABP
adducts and bladder cancer was noted (Ptrend ¼ 0.009).
Subjects possessing the highest quartile of 4-ABP adducts
exhibited an OR of 2.3 (95%CI, 1.23–4.24) relative to those
in the lowest 2 quartiles (Table 4).
Both hemoglobin adducts of 2,6-DMA and 4-ABP were
independently associated with risk of bladder cancer. A
positive association between 2,6-DMA hemoglobin
adducts and bladder cancer risk was present in both high
and low levels of 4-ABP hemoglobin adducts in all sub-
jects aswell as in separate groups stratified smoking status
at blood draw or over lifetime. Similarly, the level of 2,6-
DMA hemoglobin adducts did not modify the positive
association between 4-APB hemoglobin adducts and
bladder cancer risk (Pinteraction ¼ 0.997).
Discussion
Earlier, on the basis of data of a study in Los Angeles,
California, a high-risk region for bladder cancer, we
reported a dose-dependent, statistically significant
association between 4-ABP hemoglobin adducts, a val-
idated biomarker for 4-ABP exposure in humans, and
risk of bladder cancer unrelated to tobacco use (4). We
then examined the relationship between hemoglobin
adducts of 9 candidate alkylanilines, a subclass of ary-
lamines of which little is known about their potential
carcinogenicity to humans, using the same Los Angeles
Bladder Cancer Study data. We observed dose-depen-
dent, statistically significant associations between non-
smoking-related bladder cancer and 3 of the 9 alkylani-
line adducts, one of which was 2,6-DMA (12). These
latter 3 associations were independent of each other.
Now, our 2 sets of novel findings are being confirmed in
a low-risk population via a case–control study in Shang-
hai, China, that was initiated in parallel to our Los
Angeles study. The remarkable consistency in results
between the Los Angeles and the Shanghai studies
strongly implicate that the same class of compounds,
namely, the ayrlamines, are responsible for most cases
of bladder cancer worldwide.
Cigarette smoking is an important source of 4-ABP.
Mainstream cigarette smoke was reported to contain 4-
ABP at levels of 2.4 to 4.6 ng per cigarette (unfiltered) and
0.2 to 23 ngper cigarette (filtered; refs. 17, 18).We reported
earlier that active smokers of non-Asians in Los Angeles
had more than 3-fold 4-ABP hemoglobin adducts than
lifelong nonsmokers (75.2 vs. 22.1 pg/g hemoglobin) and
the relationship was dose-dependent (4). Consistent
with our previous findings, the levels of 4-ABP hemo-
globin adducts in the present study population also
Table 2. Level of 2,6-DMA adducts in relation to risk of bladder cancer, The Shanghai Bladder Cancer
Case-Control Study 1995–1998
2,6-DMA adducts (pg/g hemoglobin)
Undetectable Low (<115.9) High (115.9) Ptrend
Total subjects
No. cases/no. controls 348/468 46/15 90/16
OR (95% CI)a 1.00 (ref) 4.03 (2.21–7.36) 7.66 (4.41–13.29) <0.001
Fully adjusted OR (95%CI)b 1.00 (ref) 4.08 (2.16–7.70) 7.38 (4.16–13.07) <0.001
Current smokers at blood draw
No. cases/no. controls 96/181 12/5 19/4
OR (95% CI)a 1.00 (ref) 4.61 (1.57–13.58) 9.12 (3.00–27.73) <0.001
Fully adjusted OR (95%CI)b 1.00 (ref) 5.30 (1.16–16.94) 11.00 (3.15–38.42) <0.001
Nonsmokers at blood draw
No. cases/no. controls 252/287 34/10 71/12
OR (95% CI)a 1.00 (ref) 3.69 (1.78–7.68) 6.85 (3.61–12.99) <0.001
Fully adjusted OR (95%CI)b 1.00 (ref) 3.85 (1.76–8.41) 6.80 (3.52–13.13) <0.001
Lifelong nonsmokersc
No. cases/no. controls 110/195 13/6 35/9
OR (95% CI)a 1.00 (ref) 4.00 (1.45–11.02) 6.83 (3.14–14.84) <0.001
Fully adjusted OR (95%CI)d 1.00 (ref) 3.87 (1.39–10.75) 6.90 (3.17–15.02) <0.001
aAll ORs were adjusted for age at blood draw, gender, and level of education.
bAll ORs were further adjusted for smoking status at reference date (never, former, or current smokers), number of cigarettes smoked
per day at reference date (continuous), number of year of smoking (continuous), number of cigarettes per day in the past 60 days (0, 1–
<10, 10–<20, and 20 cigarettes), urinary cotinine levels (0, 1–<100, 100–<500, 500 ng/mL, or unknown).
cThose who did not smoke cigarettes at reference date or at blood draw, and exhibiting less than 75 ng/mL of urinary total cotinine.
dBesides age, gender and level of education, ORs were adjusted for urinary level of total cotinine (0 vs. 1–<75 ng/mL).
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increased with increasing number of cigarettes per day or
urinary levels of total cotinine (both Ptrend < 0.001). How-
ever, the absolute values of 4-ABP hemoglobin adducts in
Chinese in Shanghai were much lower in both current
smokers (22.43 pg/g hemoglobin) and lifelong nonsmo-
kers (17.73 pg/g hemoglobin) than their non-Asian coun-
terparts in LosAngeles, California. Althoughwe followed
the exact protocol for assays and the same standard for 4-
ABP in the 2 laboratories that conducted thequantification
of 4-ABPhemoglobin adducts, the comparison of absolute
values may not be appropriate between the 2 study
populations. The smaller difference between smokers and
nonsmokers among Shanghai Chinese compared with
that among Los Angeles non-Asians might have the
following reasons. Cigarette products consumed by Chi-
nese in Shanghai, China, may have lower 4-ABP than
those consumed by Non-Hispanic whites and blacks in
Los Angeles, California. Although there is lack of specific
data on levels of 4-ABP in cigarettes from both markets,
the level of tobacco-specific nitrosamines was >20 times
higher in U.S. brand cigarettes than in cigarettes domes-
ticallymanufactured in China (19). Another reason for the
different levels of 4-ABP hemoglobin adducts between
Shanghai Chinese and Los Angeles non-Asians might be
due to the higher prevalence of rapid N-acetylation in
Chinese than in non-Asians. N-Acetylation is a major
detoxification pathway of tobacco procarcinogens includ-
ing 4-ABP (20).
Besides tobacco smoke, there are several nonsmoking
sources of 4-ABPs that humans are exposed to. 4-
Nitrobiphenyl is a product of incomplete combustion
that has been identified as component of kerosene
heater emission (21) and diesel engine exhaust (22).
Exposure to 4-nitrobiphenyl can result in the produc-
tion of 4-ABP hemoglobin adducts (23). Therefore,
exposure to airborne 4-nitrobiphenyl could result in
elevated level of 4-ABP-Hb adducts. Fumes from heat-
ed cooking oils contain 4-ABP (24). Chinese women
usually prepare food for her family and high-temper-
ature cooking with heated oils is a common food
preparation method. Finally, 4-ABP has been detected
in commercial hair dyes (25). Women using permanent
hair dyes were found at increased risk of bladder
cancer in our previous study (26). The elevated level
of 4-ABP hemoglobin adducts among lifelong nonsmo-
kers, especially in women, could be the results of
exposure to these or as-yet-to-be-identified nonsmok-
ing sources of 4-ABP.
In the present study, patients with bladder cancer
showed significantly higher hemoglobin adducts of 2,6-
DMA than healthy control subjects in both smokers and
nonsmokers. Data on the carcinogenicity of 2,6-DMA on
humans are limited. Results from toxicologic studies are
consistent with a role for 2,6-DMA in human carcino-
genesis (9, 27). 2,6-DMA is shown to induce tumors in
nasal cavity and in the liver of rats (8, 28) and has been
classified by the IARC as a possible human carcinogen
(9). A recent mouse model study suggests that metabo-
lites of 2,6-DMA covalently bind to and produce sig-
nificant levels of DNA adducts in the bladder, ultimate-
ly leading to the malignant transformation of urothelial
cells (29). Our previous study showed that the 2,6-
DMA-Hb adduct was an independent predictor of
bladder cancer risk among non-Hispanic whites in
Los Angeles, California (12). The consistent findings
between our previous study and this study strongly
implicate a role of 2,6-DMA in the development of
bladder cancer in humans.
2,6-DMA is a metabolite of some drugs (e.g., lidocaine
and xylazine; refs. 30, 31).Humanexposure to 2,6-DMA in
patients receiving lidocaine for local anesthesia or cardiac
arrhythmias has been inferred from the resulting increase
in 2,6-DMA hemoglobin adduct levels (30). However, the
presence of 2,6-DMA hemoglobin adducts in humans not
exposed to lidocaine suggests the existence of other
sources of 2,6-DMA exposure in humans (14). 2,6-DMA
also is a principalmetabolite of the veterinary tranquilizer
xylazine (32). Xylazine residues have been found in
bovine milk and in different tissues (liver, kidney, etc.)
collected from treated cattle (32). In the United States,
xylazine is not approved by the U.S. Food and Drug
Administration (FDA) for use in food-producing animals
but it is unclear whether there is widespread practice of
Table 3. Geometricmeansof 4-ABPadductsby
cigarette smoking and urinary total cotinine
levels among control subjects only, The





(95% CI) of 4-ABP
adducts (pg/g
hemoglobin)
Total 499 19.71 (17.57–22.11)
No. of cigarettes smoked/d in the past 60 d before blood
draw
0 (nonsmokers) 309 16.06 (13.92–18.52)
<10 cigarettes/d 55 16.33 (11.88–22.44)
10–<20 cigarettes/d 57 33.95 (24.85–46.39)
20þ cigarettes/d 78 34.18 (26.18–44.64)
Ptrend <0.001
Lifetime nonsmokersa 210 15.45 (13.00–18.37)
Urinary levels of total cotinine, ng/mL
0 (undetectable) 174 15.29 (12.66–18.48)
1–<100 147 17.07 (13.89–20.98)
100–<500 68 28.24 (20.86–38.24)
500 79 32.99 (24.91–43.69)
Ptrend <0.001
Unknown cotinine level 31 19.97 (12.75–31.28)
aThose who did not smoke cigarettes at reference date or at
blooddraw, and exhibiting less than 75ng/mLof urinary total
cotinine.
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non–FDA-approved use of xylazine in China. Finally, 2,6-
DMA is used as a chemical intermediate in the manufac-
ture of pesticides, for example, metalaxyl, a systemic
fungicide used to control plant diseases. Metalaxyl is
widely used to control fungi on a variety of fruit and
vegetable crops. Humans are exposed to metalaxyl
through ingestion of fruit and vegetables with the pesti-
cide residue (33). Themaximumpesticide residue limits in
Canada are set at 1.0 ppm for apples and 5 ppm for lettuce
and other leafy vegetables (34, 35). There are similar
regulatory policy in place in European countries and the
United States. However, data regarding the allowable
levels of metalaxyl residue on food crops in China are
unavailable. Given a strong association between 2,6-DMA
hemoglobin adducts and bladder cancer risk, identifica-
tion of specific sources of 2,6-DMA exposure in the envi-
ronment should be a high priority.
Strengths of this study included the population-
based study design, relatively large sample size, and
comprehensively collected data on exposure and genet-
ic determinants of study subjects. The main limitation
of the present study was the retrospective nature of
the study design. Assessment of 4-ABP and 2,6-DMA
hemoglobin adducts was conducted on blood samples
taken after cancer diagnosis and/or treatment in cases.
It is possible that the postdiagnostic profile in these
adducts among the cases does not accurately reflect the
group’s prediagnostic profile. For example, a large
proportion of patients with bladder cancer reduced the
amount of cigarettes smoked per day or quit smoking
completely following their cancer diagnosis, thus the 4-
ABP hemoglobin adducts measured would be lower
than expected if blood samples had been collected from
patients before their cancer diagnosis. Therefore, the
present study might underestimate the effect of the 4-
ABP exposure on bladder cancer risk, especially for
smokers. Furthermore, the carcinogenic process is
believed to take decades to complete, and thus, the
relevant exposure periods are far removed from the
time of blood draw. It is unknown whether recent
exposures in study subjects, as captured by the hemo-
globin adducts of 4-ABP and 2,6-DMA, generally reflect
exposure levels in decades past. Future studies with a
prospective study design can overcome these limita-
tions and establish the temporal relation between expo-
sure to 2,6-DMA and 4-ABP and the risk of developing
bladder cancer.
In summary, the findings of the present study show
that hemoglobin adducts of 4-ABP and 2,6-DMA are
independent risk predictors of bladder cancer for life-
long nonsmokers. These consistent findings in this Chi-
nese population with our previous findings among non-
Asians in Los Angeles strongly implicate arylamines as
major causal agents of human bladder cancer. Given
that cigarette smoking accounts for only approximately
50% of the bladder cancer burden in the United States,
Table 4. Level of 4-ABP adducts in relation to risk of bladder cancer, The Shanghai Bladder Cancer Case
Control Study 1995–1998
4-ABP adducts (pg/g hemoglobin)
I/II Q (0–24.5) III Q (24.5–38.9) IV Q (38.9þ) Ptrend
Total subjects
No. cases/no. controls 256/250 122/125 106/124
OR (95% CI)a 1.00 (ref) 0.96 (0.71–1.30) 0.83 (0.61–1.14) 0.271
Fully adjusted OR (95% CI)b 1.00 (ref) 1.04 (0.74–1.46) 1.20 (0.83–1.74) 0.358
Smokers at blood draw
No. cases/no. controls 34/53 42/54 51/83
OR (95% CI)a 1.00 (ref) 1.20 (0.66–2.17) 0.95 (0.55–1.66) 0.785
Fully adjusted OR (95% CI)b 1.00 (ref) 1.39 (0.69–2.77) 1.43 (0.72–2.83) 0.345
Nonsmokers at blood draw
No. cases/no. controls 222/197 80/71 55/41
OR (95% CI)a 1.00 (ref) 1.09 (0.75–1.60) 1.31 (0.83–2.06) 0.258
Fully adjusted OR (95% CI)b 1.00 (ref) 0.99 (0.65–1.49) 1.30 (0.80–2.13) 0.376
Lifelong nonsmokers
No. cases/no. controls 94/144 33/43 31/23
OR (95% CI)a 1.00 (ref) 1.31 (0.77–2.23) 2.24 (1.21–4.14) 0.011
Fully adjusted OR (95% CI)c 1.00 (ref) 1.30 (0.76–2.22) 2.29 (1.23–4.24) 0.009
a (ORs were adjusted for age at blood draw, gender, and level of education.
bORs were further adjusted for smoking status at reference date (never, former, and current), number of cigarettes smoked per day at
reference date (continuous), number of year of smoking (continuous), number of cigarettes per day in the past 60 days (0, 1–<10, 10–
<20, and 20 cigarettes), and urinary cotinine levels (0, 1–<100, 100–<500, 500 ng/mL, or unknown).
cBesides age, gender and level of education, ORs were adjusted for urinary level of total cotinine (0 vs. 1–<75 ng/mL).
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identification of nonsmoking-related sources of 4-ABP
and 2,6-DMA in the environment should be a high
priority.
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